期刊
MOLECULAR ONCOLOGY
卷 10, 期 8, 页码 1305-1316出版社
WILEY
DOI: 10.1016/j.molonc.2016.07.001
关键词
Pancreatic cancer; Biomarker signatures; Early detection; Antibody microarrays; Recombinant antibodies
类别
资金
- VINNOVA [20011-03926]
- CREATE Health Translational Cancer Center
- Lund University Faculty of Engineering
- EU [241481 AFFINOMICS]
- BioCARE [20141023-107717]
- Invest in Skane
Pancreatic ductal adenocarcinoma (PDAC) is a disease where detection preceding clinical symptoms significantly increases the life expectancy of patients. In this study, a recombinant antibody microarray platform was used to analyze 213 Chinese plasma samples from PDAC patients and normal control (NC) individuals. The cohort was stratified according to disease stage, i.e. resectable disease (stage I/II), locally advanced (stage III) and metastatic disease (stage IV). Support vector machine analysis showed that all PDAC stages could be discriminated from controls and that the accuracy increased with disease progression, from stage I to IV. Patients with stage I/II PDAC could be discriminated from NC with high accuracy based on a plasma protein signature, indicating a possibility for early diagnosis and increased detection rate of surgically resectable tumors. (C) 2016 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据